Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer

Christopher J. DiBlasio, John B. Malcolm, Ithaar H. Derweesh, Jamie H. Womack, Matthew C. Kincade, John G. Mancini, Mitchell L. Ogles, Kimberly D. Lamar, Anthony Patterson, Robert Wake

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVE: To investigate the incidence of patient-reported erectile (ED) and sexual dysfunction and response to treatment in men after the induction of androgen deprivation therapy (ADT) for prostate cancer, as ADT-induced changes in serum testosterone can result in changes in libido and sexual function. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those receiving only neoadjuvant ADT were excluded. Variables included age, race, body mass index, prostate-specific antigen level before ADT, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), previous treatment for prostate cancer, presence of pre-existing or new-onset diabetes mellitus (DM), and presence of ED before ADT. After ADT induction, charts were reviewed for reporting of ED, changes in libido, and initiation of ED therapy (medical or surgical). RESULTS: In all, 395 patients (mean age of 71.7 years; 59.0% African-American, 41.0% Caucasian/other, at initiation ADT) were analysed. At mean follow-up of 87.4 months, 57 (14.4%) patients reported ED; 40 of these (70%) reported new-onset ED, while 17 (30%) reported ED before ADT. Response rates were 33-80% with medical therapy, including 44% receiving phosphodiesterase-5 inhibitor monotherapy. On multivariate analysis, age <70 years (P < 0.001) and the absence of DM (P = 0.024) were associated with reporting ED after ADT. CONCLUSIONS: Patients receiving ADT for prostate cancer have variable degrees of ED. Successful outcomes are possible, particularly when implementing multimodal therapy. Younger patients and those with no DM are more likely to report ED after ADT induction.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalBJU International
Volume102
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Erectile Dysfunction
Androgens
Prostatic Neoplasms
Therapeutics
Libido
Diabetes Mellitus
Phosphodiesterase 5 Inhibitors
Prostate-Specific Antigen

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. / DiBlasio, Christopher J.; Malcolm, John B.; Derweesh, Ithaar H.; Womack, Jamie H.; Kincade, Matthew C.; Mancini, John G.; Ogles, Mitchell L.; Lamar, Kimberly D.; Patterson, Anthony; Wake, Robert.

In: BJU International, Vol. 102, No. 1, 01.07.2008, p. 39-43.

Research output: Contribution to journalArticle

DiBlasio, Christopher J. ; Malcolm, John B. ; Derweesh, Ithaar H. ; Womack, Jamie H. ; Kincade, Matthew C. ; Mancini, John G. ; Ogles, Mitchell L. ; Lamar, Kimberly D. ; Patterson, Anthony ; Wake, Robert. / Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. In: BJU International. 2008 ; Vol. 102, No. 1. pp. 39-43.
@article{97593f804ef6417fac0d39bb784e40a0,
title = "Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer",
abstract = "OBJECTIVE: To investigate the incidence of patient-reported erectile (ED) and sexual dysfunction and response to treatment in men after the induction of androgen deprivation therapy (ADT) for prostate cancer, as ADT-induced changes in serum testosterone can result in changes in libido and sexual function. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those receiving only neoadjuvant ADT were excluded. Variables included age, race, body mass index, prostate-specific antigen level before ADT, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), previous treatment for prostate cancer, presence of pre-existing or new-onset diabetes mellitus (DM), and presence of ED before ADT. After ADT induction, charts were reviewed for reporting of ED, changes in libido, and initiation of ED therapy (medical or surgical). RESULTS: In all, 395 patients (mean age of 71.7 years; 59.0{\%} African-American, 41.0{\%} Caucasian/other, at initiation ADT) were analysed. At mean follow-up of 87.4 months, 57 (14.4{\%}) patients reported ED; 40 of these (70{\%}) reported new-onset ED, while 17 (30{\%}) reported ED before ADT. Response rates were 33-80{\%} with medical therapy, including 44{\%} receiving phosphodiesterase-5 inhibitor monotherapy. On multivariate analysis, age <70 years (P < 0.001) and the absence of DM (P = 0.024) were associated with reporting ED after ADT. CONCLUSIONS: Patients receiving ADT for prostate cancer have variable degrees of ED. Successful outcomes are possible, particularly when implementing multimodal therapy. Younger patients and those with no DM are more likely to report ED after ADT induction.",
author = "DiBlasio, {Christopher J.} and Malcolm, {John B.} and Derweesh, {Ithaar H.} and Womack, {Jamie H.} and Kincade, {Matthew C.} and Mancini, {John G.} and Ogles, {Mitchell L.} and Lamar, {Kimberly D.} and Anthony Patterson and Robert Wake",
year = "2008",
month = "7",
day = "1",
doi = "10.1111/j.1464-410X.2008.07505.x",
language = "English (US)",
volume = "102",
pages = "39--43",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer

AU - DiBlasio, Christopher J.

AU - Malcolm, John B.

AU - Derweesh, Ithaar H.

AU - Womack, Jamie H.

AU - Kincade, Matthew C.

AU - Mancini, John G.

AU - Ogles, Mitchell L.

AU - Lamar, Kimberly D.

AU - Patterson, Anthony

AU - Wake, Robert

PY - 2008/7/1

Y1 - 2008/7/1

N2 - OBJECTIVE: To investigate the incidence of patient-reported erectile (ED) and sexual dysfunction and response to treatment in men after the induction of androgen deprivation therapy (ADT) for prostate cancer, as ADT-induced changes in serum testosterone can result in changes in libido and sexual function. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those receiving only neoadjuvant ADT were excluded. Variables included age, race, body mass index, prostate-specific antigen level before ADT, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), previous treatment for prostate cancer, presence of pre-existing or new-onset diabetes mellitus (DM), and presence of ED before ADT. After ADT induction, charts were reviewed for reporting of ED, changes in libido, and initiation of ED therapy (medical or surgical). RESULTS: In all, 395 patients (mean age of 71.7 years; 59.0% African-American, 41.0% Caucasian/other, at initiation ADT) were analysed. At mean follow-up of 87.4 months, 57 (14.4%) patients reported ED; 40 of these (70%) reported new-onset ED, while 17 (30%) reported ED before ADT. Response rates were 33-80% with medical therapy, including 44% receiving phosphodiesterase-5 inhibitor monotherapy. On multivariate analysis, age <70 years (P < 0.001) and the absence of DM (P = 0.024) were associated with reporting ED after ADT. CONCLUSIONS: Patients receiving ADT for prostate cancer have variable degrees of ED. Successful outcomes are possible, particularly when implementing multimodal therapy. Younger patients and those with no DM are more likely to report ED after ADT induction.

AB - OBJECTIVE: To investigate the incidence of patient-reported erectile (ED) and sexual dysfunction and response to treatment in men after the induction of androgen deprivation therapy (ADT) for prostate cancer, as ADT-induced changes in serum testosterone can result in changes in libido and sexual function. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those receiving only neoadjuvant ADT were excluded. Variables included age, race, body mass index, prostate-specific antigen level before ADT, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), previous treatment for prostate cancer, presence of pre-existing or new-onset diabetes mellitus (DM), and presence of ED before ADT. After ADT induction, charts were reviewed for reporting of ED, changes in libido, and initiation of ED therapy (medical or surgical). RESULTS: In all, 395 patients (mean age of 71.7 years; 59.0% African-American, 41.0% Caucasian/other, at initiation ADT) were analysed. At mean follow-up of 87.4 months, 57 (14.4%) patients reported ED; 40 of these (70%) reported new-onset ED, while 17 (30%) reported ED before ADT. Response rates were 33-80% with medical therapy, including 44% receiving phosphodiesterase-5 inhibitor monotherapy. On multivariate analysis, age <70 years (P < 0.001) and the absence of DM (P = 0.024) were associated with reporting ED after ADT. CONCLUSIONS: Patients receiving ADT for prostate cancer have variable degrees of ED. Successful outcomes are possible, particularly when implementing multimodal therapy. Younger patients and those with no DM are more likely to report ED after ADT induction.

UR - http://www.scopus.com/inward/record.url?scp=44849130969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849130969&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.07505.x

DO - 10.1111/j.1464-410X.2008.07505.x

M3 - Article

VL - 102

SP - 39

EP - 43

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -